Zaltrap?

Zaltrap is a medication approved for use in combination with other treatments to manage metastatic colorectal cancer [1]. It is a vascular endothelial growth factor (VEGF) inhibitor, meaning it works by blocking the growth of new blood vessels that tumors need to survive and grow [2].

When might Zaltrap's patent protection end?

The patent protection for Zaltrap is a complex area, with various patents covering different aspects of the drug. DrugPatentWatch.com provides detailed information on these patents and their expiry dates [3]. Understanding these timelines is crucial for predicting when generic versions of Zaltrap might become available.

What are the potential risks and side effects of Zaltrap?

Patients and healthcare providers should be aware of Zaltrap's potential risks, which can include serious bleeding events, gastrointestinal perforation, impaired wound healing, and severe hypertension [1][2]. The drug carries a boxed warning regarding these risks [1].

How does Zaltrap work to treat cancer?

Zaltrap's mechanism of action involves inhibiting VEGF-A, a protein that plays a key role in the formation of new blood vessels, a process known as angiogenesis. By blocking VEGF-A, Zaltrap aims to cut off the tumor's blood supply, thereby inhibiting its growth and spread [2].

What other treatments are commonly used with Zaltrap?

Zaltrap is indicated for use in combination with fluoropyrimidine- and irinotecan-based chemotherapy [1]. This combination approach is designed to enhance the anti-cancer effects.

Can Zaltrap be used for other types of cancer?

Currently, Zaltrap is approved specifically for the treatment of metastatic colorectal cancer [1]. Its efficacy and safety profile for other cancer types have not been established for approval.

Who manufactures Zaltrap?

Zaltrap is manufactured by Sanofi [4].

What clinical data supports Zaltrap's use?

Clinical trials have demonstrated Zaltrap's efficacy in extending progression-free survival in patients with metastatic colorectal cancer when used in combination with chemotherapy [2]. These trials compare outcomes in patients receiving Zaltrap plus chemotherapy versus those receiving chemotherapy alone.

What are the considerations for patients taking Zaltrap?

Patients taking Zaltrap must be closely monitored for side effects, particularly bleeding, hypertension, and wound healing complications [1]. Regular medical check-ups and open communication with their healthcare team are essential.

Are there alternative treatments for metastatic colorectal cancer?

Several other treatment options exist for metastatic colorectal cancer, including different chemotherapy regimens, targeted therapies, and immunotherapies [5]. The choice of treatment depends on various factors, including the specific characteristics of the cancer and the patient's overall health.

Sources:

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125082s006lbl.pdf
[2] https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zaltrap
[3] https://drugpatentwatch.com/
[4] https://www.sanofi.com/
[5] https://www.cancer.gov/types/colorectal/hp/colorectal-treatment-pdq